Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Conditions
Brief summary
Overall survival: how long participants live after entering the study (i.e. after randomization)
Detailed description
Time for disease related symptoms to get worse (TTDD)., Safety: side effects, the number of side effects, type, severity, seriousness, and outcome., Response: measurements to indicate how many patients' tumors shrink or disappear after treatment (Overall Response)., How long the tumors stay shrunk or disappear (Duration of Response), The time during and after treatment that a participant lives without their disease getting worse (Progression Free Survival).
Interventions
DRUGETOPOSIDE
DRUGATEZOLIZUMAB
DRUGAtigotatug + Nivolumab FDC
DRUGCARBOPLATIN
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival: how long participants live after entering the study (i.e. after randomization) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time for disease related symptoms to get worse (TTDD)., Safety: side effects, the number of side effects, type, severity, seriousness, and outcome., Response: measurements to indicate how many patients' tumors shrink or disappear after treatment (Overall Response)., How long the tumors stay shrunk or disappear (Duration of Response), The time during and after treatment that a participant lives without their disease getting worse (Progression Free Survival). | — |
Countries
Austria, Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Poland, Romania, Spain
Outcome results
None listed